# Withings account plan

> Withings is a French connected-health company selling medical-grade devices and remote monitoring; profitable in FY2025 with a team of 400.

## At a glance

Withings, founded by Eric Carreel and based in France, makes clinically validated connected devices (scales, watches, blood pressure monitors, sleep analysers) for consumers and runs a B2B remote patient monitoring business for health programs, hospital networks, insurers and clinical research organisations in the US, UK and Europe. It reached full-year profitability in 2025, eight years after Carreel bought the company back from Nokia in 2018; it does not disclose absolute revenue, but says global revenue grew approximately 90% since 2018. 66% of 2025 revenue came from cleared medical devices, and 3.6 million of its 15 million active users are classified as medical users. The company has raised €61M / $71M since 2019 and has a global team of 400.

## Business units

- **Medical-grade connected devices (consumer)** (66% of 2025 revenue came from cleared medical devices): Smart scales, a sleep analyser that detects sleep apnoea, hybrid watches with medical-grade ECG, and connected blood pressure monitors, measuring over 90 biomarkers. New products in 2026 include the BodyScan 2 scale (released May 2026) and BeamO (thermometer, ECG, oxygen saturation and stethoscope). Sold at Best Buy, on Amazon and on Withings' website.
- **Withings+ subscription**: The premium version of the app sold to device owners; its revenue nearly doubled in 2025. It includes partnerships that share data with the right specialist when a trend goes the wrong way.
- **Withings Health Solutions (B2B)** (17% of total revenue): Remote patient monitoring devices and data for digital health programs, hospital networks, insurers and clinical research organisations, focused on the US and Europe and led by Antoine Pivron, Vice President, Health Solutions. B2B patient enrolment exceeds 747,000 versus about 25,500 before the buyback, and the division cites more than 300 healthcare partners. Obesity and GLP-1 care is the lead use case, with the Body Pro cellular scale shipped to patients in a kit.

## Strategic priorities

- **Obesity and GLP-1 programs as the B2B spearhead**: 500,000+ patients are enrolled in obesity care programs using Withings devices; named partners include Amba, Vitality, MedStar Health, Calibrate and 9amHealth, and a partnership with Novo Nordisk was announced in 2026.
- **Expand from weight loss to cardiometabolic care**: Withings sees its best GLP-1 partners becoming cardiometabolic health programs, routing patients to hypertension or heart failure pathways, and plans to deploy risk scores, hypertension among them.
- **Risk scores built from longitudinal measurement**: The stated strategy runs in three steps: be the champion of longitudinal measurement, build health scores such as a glucose resilience score for diabetes risk, then accompany patients between the medical system and daily life.
- **Grow recurring revenue through Withings+**: The Withings+ subscription nearly doubled its revenue in 2025 and is the bridge that moves users from consumer to patient.
- **Position for AI-led remote monitoring in the US**: Withings built a care team with medical doctors (Withings Medical) for the CMS ACCESS model for over-65 patients, and expects AI-analysed remote monitoring to spread to private US insurers and Europe.

## Latest results

Withings announced on 6 May 2026 that it reached full-year profitability in 2025, without publishing revenue, margin or net income. Global revenue has grown approximately 90% since 2018, Withings+ revenue nearly doubled in 2025, and the UK made up 6% of global revenue. Devices recorded over 1 billion health measurements in 2025, 360 million of them clinical or medical grade. By October 2026 the B2B division said it was monitoring more than 1 million patients with more than 300 healthcare partners.

## Investments and deals

- **Sustained R&D spending**: Between 2018 and 2025 Withings reinvested 20 to 27% of annual revenue in R&D; it ran 31 clinical studies in 2025 and has 150 clinical articles published to date.
- **Government-funded AI risk scores**: Risk scores were funded with a €10 million grant from the French government, and Withings has built an in-app AI agent that answers questions from the user's device data.
- **Biosency takeover**: Withings recently took over Biosency, a Rennes company doing remote monitoring of respiratory insufficiency, notably for lung cancer patients.

## Challenges and risks

- **Slow European adoption**: Pivron says European health systems are slower than the US, pay providers on activity rather than outcomes and were not built for chronic conditions, so the business team spends effort educating the market.
- **Doctor-gated enrolment in the US**: US remote monitoring adoption has been slow because a doctor must enrol each patient, which is why Withings is betting on the ACCESS model.
- **Reimbursement tied to proving outcomes**: US payers invest when they can measure engagement, retention and outcomes, so Withings must keep producing retention data; it cites 97% retention at six months and 93% at 12 months for GLP-1 patients with its support.
- **Health culture in France**: Carreel says the French have subcontracted their health to the medical world and wait until things go badly, leaving education to do before prevention products sell.

## What leadership says

> "The global healthcare conversation has shifted. Longevity, prevention, and at-home monitoring are no longer niche." — Eric Carreel, Chairman and Co-founder, UK corporate press release on 2025 profitability, 6 May 2026

> "Most of our uh best partners in the GLP1 space, they are not weight loss programs anymore. They are cardio metabolic health programs." — Antoine Pivron, Vice President, Health Solutions, Healthcare IT Today video interview, 16 October 2026

> "The challenge today is not technology. The technology already exists." — Antoine Pivron, Vice President, Health Solutions, PharmaShots Q&A around HLTH Europe 2026, 19 June 2026


## Where a supplier can help

- **Payer and pharma outcome reporting**: Tied to the reimbursement challenge: tools or data services that help Withings show engagement, retention and outcomes to US payers and pharma partners.
- **Clinical and care-team operations**: Tied to the ACCESS model priority: staffing, telehealth or workflow software for the Withings Medical care team that interacts with over-65 patients.
- **Market education in Europe**: Tied to the slow European adoption challenge: medical marketing, provider education and market-access support for remote monitoring in European health systems.
- **Device logistics for B2B kits**: Tied to the obesity and GLP-1 priority: fulfilment, cellular connectivity and kitting for Body Pro scales shipped to patients with the drug.
- **AI and data infrastructure for risk scores**: Tied to the risk-score priority and the AI investment: data, model validation and clinical study support for new cardiometabolic scores.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [The Buyback from Nokia Pays Off: Withings Confirms Full-Year Profitability for 2025 (UK corporate press release)](https://media-cdn.withings.com/press/press-releases/withings-nokia/Withings_UK_Corporate_PR.docx.pdf)

Report · 2026-05-06

- Withings, the French connected-health company, says it reached full-year profitability in 2025, eight years after founder Eric Carreel bought it back from Nokia (which had acquired it two years earlier for €164 million).
- Global revenue has grown approximately 90% since 2018; absolute revenue is not disclosed ("All financial figures are approximate based on internal Withings data").
- 66% of 2025 revenue came from cleared medical devices; 3.6 million of its 15 million active users are classified as medical users; over 1 billion health measurements in 2025, 360 million of them clinical or medical grade.
- Withings Health Solutions (B2B remote patient monitoring for digital health programs, hospital networks, insurers and clinical research organisations) generates 17% of total revenue; B2B patient enrolment exceeds 747,000 versus about 25,500 before the buyback.
- Obesity and GLP-1 care is the lead B2B use case: 500,000+ patients enrolled in obesity care programs using Withings devices; named partners include Amba, Vitality, MedStar Health, Calibrate and 9amHealth.
- The Withings+ subscription nearly doubled its revenue in 2025; R&D has absorbed 20 to 27% of annual revenue since 2018; 31 clinical studies in 2025 and 150 clinical articles to date.
- Funding: €61M / $71M raised since 2019; a global team of 400. The UK is in Withings' top five markets with 6% of global revenue.

### [Monde Numérique: Détecter la maladie avant les symptômes grâce aux objets connectés (Éric Carreel, Withings)](https://mondenumerique.info/podcast/monde-numerique/episode/detecter-la-maladie-avant-les-symptomes-grace-aux-objets-connectes-eric-carreel-withings)

Podcast · Éric Carreel, Co-founder and President · 2026-10-01

- Carreel presents BodyScan 2 (released May 2026, priced 499) as a medical check-up at home: segmental body composition, visceral fat, cardiac parameters, arterial stiffness and nerve health, combined into a "glucose resilience" score that estimates diabetes risk.
- Withings plans to push BodyScan 2 into doctors' surgeries and gyms as well as homes.
- BeamO (thermometer, ECG, oxygen saturation and stethoscope in one device) now adds automatic analysis of lung and heart sounds; ECG recordings can be sent from the app to a cardiologist who reviews them in minutes.
- All these devices carry medical certifications in Europe and the US.
- Withings recently acquired Biosency (Rennes), which does remote monitoring of respiratory insufficiency; in the US Withings has done remote monitoring for years.
- Strategy in three steps: longitudinal measurement, then risk scores, then accompanying patients between daily life and the medical system, to optimise doctor time and insurance costs. The US Medicare ACCESS program (devices + AI, no doctor in the loop) is the model; Withings wants to move European rules the same way: "in five years, we'll talk about nothing else" (translated).
- At-home sample collection (e.g. blood) is coming: "We'll have things to tell you about that in the future" (translated).

### [Healthcare IT Today: Withings, A Shift With or Without Permission From the Health Care System (interview with Antoine Pivron)](https://www.youtube.com/watch?v=eP7oDqEVdFM)

Video · Antoine Pivron, Vice President, Health Solutions (B2B division) · 2026-10-16

- Pivron joined seven years ago to build Withings' B2B division (remote patient monitoring); it now has more than 300 healthcare partners and more than 1 million actively monitored patients, focused on the US and Europe, and works with "most of the biggest GLP1 programs in the world".
- BodyScan 2 measures more than 60 biomarkers; it is sold to consumers (Best Buy, Amazon, withings.com), while the B2B version, Body Pro, is a cellular scale shipped to patients with no app, sync or setup, sending data straight to care teams.
- B2B features built for obesity care: a hidden-weight mode with motivational messages preconfigured by the care team, which he says raises engagement and retention.
- Best GLP-1 partners are now cardiometabolic health programs rather than weight-loss programs; his standard of care is drug + service + data.
- Risk scores (hypertension first) funded by a €10 million French government grant, built in about a year to a year and a half thanks to AI; an in-app AI agent answers questions using the user's own data history.
- In the US, Withings built Withings Medical, a care team with medical doctors for over-65 patients eligible for the CMS ACCESS model.
- He says Europe pays doctors per visit, so adoption is slow; technology is "five 10 years ahead of the market adoptions", and the shift will come "With or without permission from the system".

### [PharmaShots: HLTH Europe 2026, How Withings Is Advancing GLP-1 Outcomes Through Connected Care and Real-World Data](https://pharmashots.com/33964/hlth-europe-2026-how-withings-is-advancing-glp-1-outcomes-through-connected-care-and-real-world-data)

Executive talk · Antoine Pivron, Vice President, Health Solutions · 2026-06-19

- Pivron leads Withings' B2B healthcare business in the US and Europe, reporting to founder Eric Carreel; since helping launch Health Solutions in 2019 he has supported more than one million patients with over 300 healthcare partners.
- Withings monitors more than half a million GLP-1 patients through connected devices and caregiver-supported programs; obesity care is "a significant portion" of the business.
- Retention: 50% at six months on GLP-1 medication alone, versus 97% at six months and 93% at 12 months when medication is combined with services and data-driven support (as stated in the interview).
- Recently announced a partnership with Novo Nordisk, combining data, digital solutions and therapeutics.
- US payers invest when engagement, retention and outcomes can be measured; Europe's activity-based pay for providers is the obstacle; reimbursement will shift to outcomes.
- Within the next few months Withings plans risk scoring of cardiovascular factors (hypertension, diabetes) from a connected scale, accelerated by AI; every employee is encouraged to adopt AI.

## Questions about Withings

### What does Withings do?

Withings makes medical-grade connected health devices such as smart scales, ECG watches and blood pressure monitors, and sells remote patient monitoring to health programs, hospitals, insurers and research organisations through its Health Solutions division.

### Is Withings profitable?

Yes. Withings says it reached full-year profitability in 2025. It does not publish absolute revenue, but says global revenue grew approximately 90% since 2018.

### How many employees does Withings have?

Withings cites a global team of 400.

### Who leads Withings?

Eric Carreel, co-founder, who bought the company back from Nokia in 2018. Antoine Pivron leads the B2B Health Solutions division.

### What is Withings' strategy?

To grow recurring Withings+ revenue and expand B2B remote monitoring around chronic conditions, led by obesity and GLP-1 programs and moving toward cardiometabolic risk scores.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
